In pulmonary carcinomas, EGFR mutation is associated with Asians, females, non-smokers, and the adenocarcinoma type, and it has become evident that EGFR tyrosine kinase inhibitors are highly effective for pulmonary adenocarcinomas with EGFR mutations [17, 18]. Here, EGFR is linked to adenocarcinoma.